药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Abituzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Abituzumab.
Tiludronic acid
Sifalimumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sifalimumab.
Tiludronic acid
Demcizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Demcizumab.
Tiludronic acid
Carlumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Carlumab.
Tiludronic acid
Intetumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Intetumumab.
Tiludronic acid
Ibalizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ibalizumab.
Tiludronic acid
Lumretuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lumretuzumab.
Tiludronic acid
Tovetumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tovetumab.
Tiludronic acid
Dacetuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dacetuzumab.
Tiludronic acid
Bimagrumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bimagrumab.
Tiludronic acid
Blosozumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Blosozumab.
Tiludronic acid
Mavrilimumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Mavrilimumab.
Tiludronic acid
Inebilizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Inebilizumab.
Tiludronic acid
Plozalizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Plozalizumab.
Tiludronic acid
Mogamulizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Mogamulizumab.
Tiludronic acid
Mirvetuximab Soravtansine
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Mirvetuximab Soravtansine.
Tiludronic acid
Bococizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bococizumab.
Tiludronic acid
Indusatumab vedotin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Indusatumab vedotin.
Tiludronic acid
Fresolimumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Fresolimumab.
Tiludronic acid
Dusigitumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dusigitumab.